(17078830), Q. X., (17078833), K. H., (17078836), X. M., (17078839), Y. W., (17078842), L. Z., (17078845), L. B., . . . (17078857), Q. C. (2025). Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Chicago Style (17. basım) Atıf(17078830), Qingsheng Xu, et al. Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.
MLA (9th ed.) Atıf(17078830), Qingsheng Xu, et al. Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..